Current File : //var/www/html/shaban/duassis/api/public/storage/86fviuv/cache/d4128b74d582198057d9a64be4dcc351
a:5:{s:8:"template";s:9437:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%7CRoboto%3A100%2C300%2C400%2C500%2C600%2C700%2C900%7CRaleway%3A600%7Citalic&subset=latin%2Clatin-ext" id="quality-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css"> html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background:0 0}a:active,a:hover{outline:0}@media print{*{color:#000!important;text-shadow:none!important;background:0 0!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}p{orphans:3;widows:3}.navbar{display:none}}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:62.5%;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#428bca;text-decoration:none}a:focus,a:hover{color:#2a6496;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-md-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:992px){.col-md-12{float:left}.col-md-12{width:100%}}.collapse{display:none} .nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{max-height:340px;padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:0;margin-left:0}}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}.navbar-nav.navbar-right:last-child{margin-right:-15px}}@media (min-width:768px){.navbar-right{float:right!important}}.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container-fluid:after,.container:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}html{font-size:14px;overflow-y:scroll;overflow-x:hidden;-ms-overflow-style:scrollbar}@media(min-width:60em){html{font-size:16px}}body{background:#fff;color:#6a6a6a;font-family:"Open Sans",Helvetica,Arial,sans-serif;font-size:1rem;line-height:1.5;font-weight:400;padding:0;background-attachment:fixed;text-rendering:optimizeLegibility;overflow-x:hidden;transition:.5s ease all}p{line-height:1.7;margin:0 0 25px}p:last-child{margin:0}a{transition:all .3s ease 0s}a:focus,a:hover{color:#121212;outline:0;text-decoration:none}.padding-0{padding-left:0;padding-right:0}ul{font-weight:400;margin:0 0 25px 0;padding-left:18px}ul{list-style:disc}ul>li{margin:0;padding:.5rem 0;border:none}ul li:last-child{padding-bottom:0}.site-footer{background-color:#1a1a1a;margin:0;padding:0;width:100%;font-size:.938rem}.site-info{border-top:1px solid rgba(255,255,255,.1);padding:30px 0;text-align:center}.site-info p{color:#adadad;margin:0;padding:0}.navbar-custom .navbar-brand{padding:25px 10px 16px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{color:#f8504b}a{color:#f8504b}.navbar-custom{background-color:transparent;border:0;border-radius:0;z-index:1000;font-size:1rem;transition:background,padding .4s ease-in-out 0s;margin:0;min-height:100px}.navbar a{transition:color 125ms ease-in-out 0s}.navbar-custom .navbar-brand{letter-spacing:1px;font-weight:600;font-size:2rem;line-height:1.5;color:#121213;margin-left:0!important;height:auto;padding:26px 30px 26px 15px}@media (min-width:768px){.navbar-custom .navbar-brand{padding:26px 10px 26px 0}}.navbar-custom .navbar-nav li{margin:0 10px;padding:0}.navbar-custom .navbar-nav li>a{position:relative;color:#121213;font-weight:600;font-size:1rem;line-height:1.4;padding:40px 15px 40px 15px;transition:all .35s ease}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0}@media (max-width:991px){.navbar-custom .navbar-nav{letter-spacing:0;margin-top:1px}.navbar-custom .navbar-nav li{margin:0 20px;padding:0}.navbar-custom .navbar-nav li>a{color:#bbb;padding:12px 0 12px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0;color:#fff}.navbar-custom li a{border-bottom:1px solid rgba(73,71,71,.3)!important}.navbar-header{float:none}.navbar-collapse{border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.collapse{display:none!important}.navbar-custom .navbar-nav{background-color:#1a1a1a;float:none!important;margin:0!important}.navbar-custom .navbar-nav>li{float:none}.navbar-header{padding:0 130px}.navbar-collapse{padding-right:0;padding-left:0}}@media (max-width:768px){.navbar-header{padding:0 15px}.navbar-collapse{padding-right:15px;padding-left:15px}}@media (max-width:500px){.navbar-custom .navbar-brand{float:none;display:block;text-align:center;padding:25px 15px 12px 15px}}@media (min-width:992px){.navbar-custom .container-fluid{width:970px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}}@media (min-width:1200px){.navbar-custom .container-fluid{width:1170px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}} @font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(http://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfChc9.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfChc9.ttf) format('truetype')} </style>
</head>
<body class="">
<nav class="navbar navbar-custom" role="navigation">
<div class="container-fluid padding-0">
<div class="navbar-header">
<a class="navbar-brand" href="#">
{{ keyword }}
</a>
</div>
<div class="collapse navbar-collapse" id="custom-collapse">
<ul class="nav navbar-nav navbar-right" id="menu-menu-principale"><li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-169" id="menu-item-169"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-121" id="menu-item-121"><a href="#">Location</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-120" id="menu-item-120"><a href="#">Menu</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-119" id="menu-item-119"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-122" id="menu-item-122"><a href="#">Contacts</a></li>
</ul> </div>
</div>
</nav>
<div class="clearfix"></div>
{{ text }}
<br>
{{ links }}
<footer class="site-footer">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="site-info">
<p>{{ keyword }} 2021</p></div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:10231:"The vaccine is approved in Singapore for the prevention of dengue infection caused by dengue virus serotypes 1, 2, 3 ⦠The vaccine, called Dengvaxia, is aimed at helping children in Puerto Rico and other U.S. territories where dengue is a problem. MANILA, Philippines â The civil suit for damages filed against Sanofi Pasteur, the maker of the Dengvaxia vaccine, and its local distributor Zuellig Pharma will push through. An experimental dengue vaccine has shown promising early results in ⦠How the Dengvaxia Scandal Might Destroy a Good Vaccine. President Rodrigo Duterte in 2018 stopped use and sale of the anti-dengue vaccine Dengvaxia in the country after its maker admitted that it could cause severe symptoms of the mosquito-borne disease in some cases. A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people ages 9-45 years old. Dengvaxia is the result of over 20 years of research and development and is the first vaccine approved for the prevention of dengue, a serious mosquito-borne disease that weighs heavily on public health systems throughout the world. Experts on the FDAâs vaccines committee evenly split on Dengvaxiaâs safety in people 9 to 45 years old, and decided against its effectiveness in the broad age group by 7-6 with one abstention. âDengvaxia has side effects as admitted by Sanofi (Dengvaxia maker Sanofi Pasteur) in December 2016 before the vaccine was bought -allergic anaphylactic reaction, viscerotropism, neurotropism and/ or severe dengue,â she explained. New dengue vaccine performs well in large trial, but safety remains key concern. CHICAGO - The US Food and Drug Administration on Wednesday gave Sanofi SA's dengue vaccine Dengvaxia a very narrow approval as the company continues to suffer from evidence that its vaccine, which took 20 years to develop, can cause severe infections in some people. During a large scale clinical efficacy trial of the Sanofipasteur live-attenuated tetravalent dengue vaccine (Dengvaxia), features of hospitalized disease accompanying dengue infections in placebo recipients were closely similar to those in vaccinated children. The vaccine was first withdrawn from the market after the manufacturer disclosed in late 2017 that Dengvaxia may cause "severe disease" among those who have not ⦠She pointed out that the DOH has even declared 87 deaths possibly caused by the vaccine as of last month. In 2015, Sanofi Pasteur introduced the first dengue vaccine which is registered in several of the most endemic countries in the world. Dengvaxia (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. The World Health Organization recommends that the vaccine only be given to persons with confirmed prior dengue virus infection. More than 830,000 children received the Dengvaxia vaccine under the campaign. The vaccine released for commercialization in Brazil is a tetravalent, recombinant, chimeric live virus dengue vaccine called CYD-TDV that was developed by Sanofi Pasteur and marketed under the name Dengvaxia® . 16 Dengvaxia®, developed by Sanofi Pasteur, is the first available dengue vaccine against all four strains of dengue virus (DEN-1, DEN-2, DEN-3, and DEN-4). vaccine. Many Filipinos have not forgotten the botched launch of the anti-dengue vaccine Dengvaxia in 2016 under Duterteâs predecessor Benigno Aquino III. However, the age specific hospitalizat ⦠The FDA says the drug may only be given to ⦠Brazil launches first dengue vaccine campaign: drug maker Brazil on Saturday launched the first public immunisation programme in the Americas against dengue fever, ⦠Metro Manila (CNN Philippines, December 6) â The "irresponsible noise-making" during the Dengvaxia scare should be avoided when the country starts the distribution of vaccines ⦠French pharmaceutical firm Sanofi Pasteur on Wednesday, Feb. 3, gave the assurance that it was respecting the legal processes in the Philippines where its executives are facing charges concerning its anti-dengue vaccine Dengvaxia. CYD-TDV, sold under the brand name Dengvaxia and made by Sanofi Pasteur, is a live attenuated tetravalent chimeric vaccinemade using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of the yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes. Dengue Vaccine Maker Struggles to Find a Diagnostic That Will Make Its Product Safe to Use. The government halted the immunisation drive in 2017 after French ⦠But vaccine manufacturer Sanofi Pasteur on Wednesday reported that Dengvaxia should not be recommended to individuals who have never been infected with the dengue virus. Sanofi maintains confidence in Dengvaxia. The company said a new analysis shows that, for dengue-naive recipients, the vaccine makes future dengue episodes more severe. However, a small number of patients develop severe disease, with The polio immunization drive also faced a scare involving another vaccine. 13 December 2017 - Following a consultation of the Global Advisory Committee on Vaccine Safety, the World Health Organization (WHO) finds that the dengue vaccine CYD-TDV, sold under the brand name Dengvaxia, prevents disease in the majority of vaccine recipients but it should not be administered to people who have not previously been infected with dengue virus. Health Undersecretary Maria Rosario Vergeire, in the Laging Handa briefing on Saturday, clarified that all manufacturers required indemnification agreements, as Covid-19 vaccines are still under development. On Dec. 1, 2015, Aquino appeared in earnest about solving the epidemic (eventually clarified in court cases as upon the advice then-Health secretary Janette Garin) by going to Paris to discuss a deal with Sanofi Pasteur Inc., the manufacturer of Dengvaxia, for the use of the vaccine on Filipino children â the first in Asia to be so vaccinated. Dengvaxia is a vaccine used to help protect against dengue disease. But this vaccine ⦠Notably, the same Dr. Fauci and his NIAID owns the patent on a vaccine for dengue fever known as Dengvaxia, marketed by Sanofi-Pasteur and promoted as an âessentialâ vaccine by Tedrosâ WHO since 2016. Recent surveys reveal that most Filipinos are hesitant to get COVID-19 vaccines, about 3 years after the Dengvaxia issue. âIyon po talaga ang hinihingi ng mga manufacturer; marami po talaga ang natatakot dahil sa experience sa Dengvaxia na naihabla po ang Sanofi kasi ⦠Dengue Vaccine Globally. âSanofi Pasteur, Inc. respects the ongoing legal ⦠4.3 Contraindications ⢠Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or after prior administration of Dengvaxia or a vaccine containing the same components. Metro Manila (CNN Philippines, February 17) â American vaccine manufacturer Pfizer is worried it might suffer the same fate as pharmaceutical firm ⦠What is Dengvaxia and how is it used? Dengvaxia-maker Sanofi Pasteur assures it respects legal processes in PH where execs face charges. A leading epidemiologist walks us through the Dengvaxia scandal, and ponders its impact on vaccines in general. As ⦠The demand for indemnification agreements by Covid-19 vaccine manufacturers is not related to the Dengvaxia controversy, the Department of Health (DoH) said. For instructions on reconstitution of Dengvaxia before administration, see section 6.6. The governmentâs immunization programs were marred in 2017 by a dengue fever vaccine made by French drug maker Sanofi Pasteur which some Philippine officials linked to ⦠The Dengvaxia vaccine is said to be capable of lowering severity in dengue cases by 93 percent and reducing hospitalization rate by 82 percent, health officials said. Dengue disease is a mosquito-borne tropical disease caused by the dengue virus leading to mild, flu-like symptoms in most people. The vaccine was touted as ⦠Pharmaceutical giant Sanofi Pasteur should set aside a fund to help children who may suffer severe dengue symptoms after taking the controversial vaccine Dengvaxia, a ⦠The drug trials conducted by the maker of Dengvaxia, French drug company Sanofi Pasteur, did not screen all participants for previous dengue infection. DOH urged to demand P3-billion refund from Dengvaxia maker. Then came the vaccineâs rollout in the Philippinesâand a ⦠... been asked to demand P3 billion in full refund from French pharmaceutical giant Sanofi Pasteur for the controversial Dengvaxia vaccine. Brazil on Saturday launched the first public immunisation programme in the Americas against dengue fever, with 500,000 people to be injected with the world's first authorized vaccine against the disease, French pharmaceutical giant Sanofi said. Dengvaxia maker wins US approval but with major restrictions. French pharma giant Sanofi believed its dengue fever shot would defeat an insidious illness. On December 1, 2015, former President Benigno Aquino III met with executives of Sanofi Pasteur in a courtesy call in Paris, making the Philippines the first Asian country to approve the commercial sale of Dengvaxia. The Food and Drug Administration (FDA) has ordered Sanofi Pasteur to stop the sale, distribution and marketing of its Dengvaxia vaccine in the Philippines after the French drug maker ⦠By Jon Cohen Nov. 6, 2019 , 5:00 PM. Evidence indicates that CYD-TDV is partially effective in preventing infection, but may lead to a higher risk of severe disease in those who have not been previo⦠Dengvaxia is approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas. When ⦠Sanofi and former government officials in the Philippines are under mounting pressure from lawmakers there over the rollout of Dengvaxia. Yesterday Sanofi Pasteur, maker of Dengvaxia, a promising dengue vaccine, announced it was changing the labeling on the vaccine to limit its use to people who have had previous exposure to dengue virus. ";s:7:"keyword";s:23:"dengvaxia vaccine maker";s:5:"links";s:702:"<a href="https://api.duassis.com/storage/86fviuv/microwave-transmitter">Microwave Transmitter</a>,
<a href="https://api.duassis.com/storage/86fviuv/deathloop-main-character">Deathloop Main Character</a>,
<a href="https://api.duassis.com/storage/86fviuv/lancaster-country-club-pa-membership-cost">Lancaster Country Club Pa Membership Cost</a>,
<a href="https://api.duassis.com/storage/86fviuv/science-behind-covid-19">Science Behind Covid-19</a>,
<a href="https://api.duassis.com/storage/86fviuv/how-to-be-a-better-boyfriend%2Fhusband">How To Be A Better Boyfriend/husband</a>,
<a href="https://api.duassis.com/storage/86fviuv/living-in-brier-creek-country-club">Living In Brier Creek Country Club</a>,
";s:7:"expired";i:-1;}
Mini Shell